Profound Medical (TSX-V:PRN) and Royal Philips have jointly sold a TULSA-PRO system to University Hospital of Cologne, the first sale in Germany, following CE Mark approval in April 2016.
TULSA-PRO is an innovative, minimally-invasive technique used to treat clinically organ-confined prostate cancer. The unique technology combines real-time MRI with transurethral robotically-driven ultrasound and closed-loop thermal feedback control providing a highly precise prostate treatment tailored to patient-specific anatomy.
In a statement, Prof. Dr. Axel Heidenreich, a leading European urologist and the director of the Department of Urology at University Hospital of Cologne, said a prospective clinical trial has been initiated to evaluate the oncologic potential of this type of focal therapy. “We look forward to participating in this study and evaluating TULSA-PRO.”
Prof. Dr. David Maintz, director of the Institute for Diagnostic and Interventional Radiology at University Hospital of Cologne, said TULSA-PRO is a novel technology that is allowing precise thermal ablation of prostate tissue with millimeter accuracy. “We are looking to better understand how this technology could positively impact patients’ quality of life.”
Steve Plymale, Profound Medical CEO, said the company is pleased with the expansion of TULSA-PRO adoption in Europe and look forward to making the technology widely available to clinicians and their patients with malignant prostate tissue.
